Bots, editor, reviewer, Administrators
13,951
edits
Feed:All articles/Pretty: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
"topic" : "all", | "topic" : "all", | ||
"articles" : [ | "articles" : [ | ||
{ | { | ||
"timestamp" : "2017-12-14T19:22:25Z", | "timestamp" : "2017-12-14T19:22:25Z", | ||
| Line 32: | Line 13: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Scandinavian Simvastatin Survival Study", | "expansion" : "Scandinavian Simvastatin Survival Study", | ||
"briefResultsDescription" : "Simvastatin reduces all mortality in stable CAD", | "briefResultsDescription" : "Simvastatin reduces all mortality in stable CAD", | ||
"published" : "1994-11-19", | "published" : "1994-11-19", | ||
| Line 51: | Line 31: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "African-American Heart Failure Trial", | "expansion" : "African-American Heart Failure Trial", | ||
"briefResultsDescription" : "Improved survival among black patients with HF", | "briefResultsDescription" : "Improved survival among black patients with HF", | ||
"published" : "2004-11-11", | "published" : "2004-11-11", | ||
| Line 59: | Line 38: | ||
"title" : "Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure", | "title" : "Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure", | ||
"pmid" : "15533851" | "pmid" : "15533851" | ||
}, | }, | ||
{ | { | ||
| Line 89: | Line 49: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension", | "expansion" : "Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension", | ||
"briefResultsDescription" : "Benazepril/amlodipine is associated with fewer CV events", | "briefResultsDescription" : "Benazepril/amlodipine is associated with fewer CV events", | ||
"published" : "2008-12-04", | "published" : "2008-12-04", | ||
| Line 108: | Line 67: | ||
"subspecialties" : "Endocrinology", | "subspecialties" : "Endocrinology", | ||
"expansion" : "Action to Control Cardiovascular Risk in Diabetes", | "expansion" : "Action to Control Cardiovascular Risk in Diabetes", | ||
"briefResultsDescription" : "Increased mortality and no cardiovascular benefit with intensive glycemic control", | "briefResultsDescription" : "Increased mortality and no cardiovascular benefit with intensive glycemic control", | ||
"published" : "2008-06-12", | "published" : "2008-06-12", | ||
| Line 127: | Line 85: | ||
"subspecialties" : "Endocrinology", | "subspecialties" : "Endocrinology", | ||
"expansion" : "ACCORD Study Group", | "expansion" : "ACCORD Study Group", | ||
"briefResultsDescription" : "Intensive BP control doesn't reduce CV events in T2DM", | "briefResultsDescription" : "Intensive BP control doesn't reduce CV events in T2DM", | ||
"published" : "2010-03-14", | "published" : "2010-03-14", | ||
| Line 146: | Line 103: | ||
"subspecialties" : "Cardiology;Endocrinology", | "subspecialties" : "Cardiology;Endocrinology", | ||
"expansion" : "Action to Control Cardiovascular Risk in Diabetes-Lipid", | "expansion" : "Action to Control Cardiovascular Risk in Diabetes-Lipid", | ||
"briefResultsDescription" : "Fenofibrates don't reduce CVD among adults with T2DM on statins", | "briefResultsDescription" : "Fenofibrates don't reduce CVD among adults with T2DM on statins", | ||
"published" : "2010-04-29", | "published" : "2010-04-29", | ||
| Line 165: | Line 121: | ||
"subspecialties" : "Oncology;Surgery", | "subspecialties" : "Oncology;Surgery", | ||
"expansion" : "The American College of Surgeons Oncology Group (ACOSOG) Z0011", | "expansion" : "The American College of Surgeons Oncology Group (ACOSOG) Z0011", | ||
"briefResultsDescription" : "ALND no better than monitoring in SLNB-positive disease", | "briefResultsDescription" : "ALND no better than monitoring in SLNB-positive disease", | ||
"published" : "2011-02-09", | "published" : "2011-02-09", | ||
| Line 173: | Line 128: | ||
"title" : "Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial", | "title" : "Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial", | ||
"pmid" : "21304082" | "pmid" : "21304082" | ||
}, | }, | ||
{ | { | ||
| Line 279: | Line 139: | ||
"subspecialties" : "Critical Care", | "subspecialties" : "Critical Care", | ||
"expansion" : "Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock", | "expansion" : "Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock", | ||
"briefResultsDescription" : "Hydrocortisone provides no benefit in 90-day mortality", | "briefResultsDescription" : "Hydrocortisone provides no benefit in 90-day mortality", | ||
"published" : "2018-01-19", | "published" : "2018-01-19", | ||
| Line 298: | Line 157: | ||
"subspecialties" : "Endocrinology", | "subspecialties" : "Endocrinology", | ||
"expansion" : "Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation", | "expansion" : "Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation", | ||
"briefResultsDescription" : "Intensive therapy reduces microvascular complications", | "briefResultsDescription" : "Intensive therapy reduces microvascular complications", | ||
"published" : "2008-06-06", | "published" : "2008-06-06", | ||
| Line 317: | Line 175: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Atrial Fibrillation Follow-up Investigation of Rhythm Management", | "expansion" : "Atrial Fibrillation Follow-up Investigation of Rhythm Management", | ||
"briefResultsDescription" : "No mortality difference, trend towards harm with rhythm control", | "briefResultsDescription" : "No mortality difference, trend towards harm with rhythm control", | ||
"published" : "2002-11-05", | "published" : "2002-11-05", | ||
| Line 327: | Line 184: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2018-07-03T03:04:07Z", | |||
"briefDesignDescription" : "Daily albumin in severe sepsis", | |||
"timestamp" : "2018-07-03T03:04:07Z", | |||
"briefDesignDescription" : "Daily albumin in severe sepsis", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1305727", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1305727", | ||
"pageid" : 1781, | "pageid" : 1781, | ||
| Line 412: | Line 193: | ||
"subspecialties" : "Critical Care", | "subspecialties" : "Critical Care", | ||
"expansion" : "Albumin Italian Outcome Sepsis", | "expansion" : "Albumin Italian Outcome Sepsis", | ||
"briefResultsDescription" : "Daily albumin with no mortality benefit at 28 days", | "briefResultsDescription" : "Daily albumin with no mortality benefit at 28 days", | ||
"published" : "2014-03-18", | "published" : "2014-03-18", | ||
| Line 420: | Line 200: | ||
"title" : "Albumin replacement in patients with severe sepsis or septic shock", | "title" : "Albumin replacement in patients with severe sepsis or septic shock", | ||
"pmid" : "24635772" | "pmid" : "24635772" | ||
}, | }, | ||
{ | { | ||
| Line 450: | Line 211: | ||
"subspecialties" : "Nephrology;Cardiology", | "subspecialties" : "Nephrology;Cardiology", | ||
"expansion" : "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial", | "expansion" : "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial", | ||
"briefResultsDescription" : "Chlorthalidone performs similarly to lisinopril and amlodipine", | "briefResultsDescription" : "Chlorthalidone performs similarly to lisinopril and amlodipine", | ||
"published" : "2002-12-18", | "published" : "2002-12-18", | ||
| Line 469: | Line 229: | ||
"subspecialties" : "Nephrology;Rheumatology", | "subspecialties" : "Nephrology;Rheumatology", | ||
"expansion" : "Aspreva Lupus Management Study", | "expansion" : "Aspreva Lupus Management Study", | ||
"briefResultsDescription" : "MMF similar to cyclophosphamide in lupus nephritis", | "briefResultsDescription" : "MMF similar to cyclophosphamide in lupus nephritis", | ||
"published" : "2009-05-01", | "published" : "2009-05-01", | ||
| Line 479: | Line 238: | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2016-04-01T23:26:41Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed", | ||
"fulltexturl" : "http://www. | "fulltexturl" : "http://www.gastrojournal.org/article/S0016-5085(06)01535-6/fulltext", | ||
"pageid" : | "pageid" : 82, | ||
"pdfurl" : "http://www. | "pdfurl" : "http://www.gastrojournal.org/article/S0016-5085(06)01535-6/pdf", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"citation" : "Fernández J, <i>et al</i>. \"Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage\". <i>Gastroenterology</i>. 2006. 131(4):1049-56.", | |||
"subspecialties" : "Gastroenterology;Infectious Disease", | |||
"expansion" : "", | |||
"citation" : "Fernández J, <i>et al</i>. \"Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage\". <i>Gastroenterology</i>. 2006. 131(4):1049-56.", | |||
"subspecialties" : "Gastroenterology;Infectious Disease", | |||
"expansion" : " | |||
"briefResultsDescription" : "Ceftriaxone reduces the incidence of bacterial infection", | "briefResultsDescription" : "Ceftriaxone reduces the incidence of bacterial infection", | ||
"published" : "2006-10-01", | "published" : "2006-10-01", | ||
| Line 602: | Line 265: | ||
"subspecialties" : "Surgery;Infectious Disease", | "subspecialties" : "Surgery;Infectious Disease", | ||
"expansion" : "Appendicitis Acuta", | "expansion" : "Appendicitis Acuta", | ||
"briefResultsDescription" : "Antibiotics not non-inferior to surgeyr", | "briefResultsDescription" : "Antibiotics not non-inferior to surgeyr", | ||
"published" : "2015-06-16", | "published" : "2015-06-16", | ||
| Line 621: | Line 283: | ||
"subspecialties" : "Critical Care", | "subspecialties" : "Critical Care", | ||
"expansion" : "Acute Respiratory Distress Syndrome Network", | "expansion" : "Acute Respiratory Distress Syndrome Network", | ||
"briefResultsDescription" : "Mortality benefit and more ventilator-free days with lung-protective strategy", | "briefResultsDescription" : "Mortality benefit and more ventilator-free days with lung-protective strategy", | ||
"published" : "2000-05-04", | "published" : "2000-05-04", | ||
| Line 629: | Line 290: | ||
"title" : "Ventilation With Lower Tidal Volumes As Compared With Traditional Tidal Volumes For Acute Lung Injury And The Acute Respiratory Distress Syndrome", | "title" : "Ventilation With Lower Tidal Volumes As Compared With Traditional Tidal Volumes For Acute Lung Injury And The Acute Respiratory Distress Syndrome", | ||
"pmid" : "10793162" | "pmid" : "10793162" | ||
}, | }, | ||
{ | { | ||
| Line 659: | Line 301: | ||
"subspecialties" : "Cardiology;Neurology", | "subspecialties" : "Cardiology;Neurology", | ||
"expansion" : "Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation", | "expansion" : "Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation", | ||
"briefResultsDescription" : "Apixaban better for CVA prevention in AF", | "briefResultsDescription" : "Apixaban better for CVA prevention in AF", | ||
"published" : "2011-09-15", | "published" : "2011-09-15", | ||
| Line 678: | Line 319: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "A Study of Cardiovascular Events in Diabetes", | "expansion" : "A Study of Cardiovascular Events in Diabetes", | ||
"briefResultsDescription" : "Aspirin reduces cardiovascular events but increases bleeding vs. placebo", | "briefResultsDescription" : "Aspirin reduces cardiovascular events but increases bleeding vs. placebo", | ||
"published" : "2018-08-26", | "published" : "2018-08-26", | ||
| Line 697: | Line 337: | ||
"subspecialties" : "Pulmonology", | "subspecialties" : "Pulmonology", | ||
"expansion" : "Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis", | "expansion" : "Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis", | ||
"briefResultsDescription" : "Pirfenidone reduces progression of IPF", | "briefResultsDescription" : "Pirfenidone reduces progression of IPF", | ||
"published" : "2014-05-29", | "published" : "2014-05-29", | ||
| Line 705: | Line 344: | ||
"title" : "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis", | "title" : "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis", | ||
"pmid" : "24836312" | "pmid" : "24836312" | ||
}, | }, | ||
{ | { | ||
| Line 735: | Line 355: | ||
"subspecialties" : "Nephrology", | "subspecialties" : "Nephrology", | ||
"expansion" : "Angioplasty and Stenting for Renal Artery Lesions", | "expansion" : "Angioplasty and Stenting for Renal Artery Lesions", | ||
"briefResultsDescription" : "Revascularization no better than medical therapy alone in RAS", | "briefResultsDescription" : "Revascularization no better than medical therapy alone in RAS", | ||
"published" : "2009-11-12", | "published" : "2009-11-12", | ||
| Line 743: | Line 362: | ||
"title" : "Revascularization versus medical therapy for renal-artery stenosis", | "title" : "Revascularization versus medical therapy for renal-artery stenosis", | ||
"pmid" : "19907042" | "pmid" : "19907042" | ||
}, | }, | ||
{ | { | ||
| Line 830: | Line 373: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "The Transthyretin Amyloidosis Cardiomyopathy Clinical Trial", | "expansion" : "The Transthyretin Amyloidosis Cardiomyopathy Clinical Trial", | ||
"briefResultsDescription" : "Tafamidis superior to placebo in amyloid cardiomyopathy", | "briefResultsDescription" : "Tafamidis superior to placebo in amyloid cardiomyopathy", | ||
"published" : "2018-08-27", | "published" : "2018-08-27", | ||
| Line 849: | Line 391: | ||
"subspecialties" : "Hematology", | "subspecialties" : "Hematology", | ||
"expansion" : "Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis", | "expansion" : "Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis", | ||
"briefResultsDescription" : "No difference with intervention vs. anticoagulation", | "briefResultsDescription" : "No difference with intervention vs. anticoagulation", | ||
"published" : "2017-12-07", | "published" : "2017-12-07", | ||
| Line 859: | Line 400: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2014-12-01T14:21:22Z", | |||
"briefDesignDescription" : "DMARD ± prednisone or infliximab in RA", | |||
"fulltexturl" : "http://onlinelibrary.wiley.com/doi/10.1002/art.21405/abstract", | |||
"pageid" : 77, | |||
"pdfurl" : "http://onlinelibrary.wiley.com/doi/10.1002/art.21405/pdf", | |||
"trainingLevel" : "Resident", | |||
"citation" : "Goekoop-Ruiterman YP, <i>et al</i>. \"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis\". <i>Arthritis & Rheumatism</i>. 2005. 52(11):3381-3390.", | |||
"subspecialties" : "Rheumatology", | |||
"timestamp" : "2014-12-01T14:21:22Z", | |||
"briefDesignDescription" : "DMARD ± prednisone or infliximab in RA", | |||
"fulltexturl" : "http://onlinelibrary.wiley.com/doi/10.1002/art.21405/abstract", | |||
"pageid" : 77, | |||
"pdfurl" : "http://onlinelibrary.wiley.com/doi/10.1002/art.21405/pdf", | |||
"trainingLevel" : "Resident", | |||
"citation" : "Goekoop-Ruiterman YP, <i>et al</i>. \"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis\". <i>Arthritis & Rheumatism</i>. 2005. 52(11):3381-3390.", | |||
"subspecialties" : "Rheumatology", | |||
"expansion" : "Behandel-Strategeieën (\"treatment strategies\" in Dutch)", | "expansion" : "Behandel-Strategeieën (\"treatment strategies\" in Dutch)", | ||
"briefResultsDescription" : "Combination therapy produces early functional improvement than DMARD alone", | "briefResultsDescription" : "Combination therapy produces early functional improvement than DMARD alone", | ||
"published" : "2005-11-01", | "published" : "2005-11-01", | ||
| Line 992: | Line 418: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2018-01-17T21:45:20Z", | |||
"briefDesignDescription" : "LMWH bridging for surgery in AF", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1501035", | |||
"timestamp" : "2018-01-17T21:45:20Z", | |||
"briefDesignDescription" : "LMWH bridging for surgery in AF", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1501035", | |||
"pageid" : 2402, | "pageid" : 2402, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501035", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501035", | ||
| Line 1,058: | Line 427: | ||
"subspecialties" : "Cardiology;Hematology", | "subspecialties" : "Cardiology;Hematology", | ||
"expansion" : "Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for Elective Invasive Procedure or Surgery", | "expansion" : "Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for Elective Invasive Procedure or Surgery", | ||
"briefResultsDescription" : "LMWH bridging didn't reduce VTE but increased bleeding", | "briefResultsDescription" : "LMWH bridging didn't reduce VTE but increased bleeding", | ||
"published" : "2015-06-22", | "published" : "2015-06-22", | ||
| Line 1,066: | Line 434: | ||
"title" : "Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation", | "title" : "Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation", | ||
"pmid" : "26095867" | "pmid" : "26095867" | ||
}, | }, | ||
{ | { | ||
| Line 1,096: | Line 445: | ||
"subspecialties" : "Rheumatology", | "subspecialties" : "Rheumatology", | ||
"expansion" : "Computer Assisted Management in Early Rheumatoid Arthritis", | "expansion" : "Computer Assisted Management in Early Rheumatoid Arthritis", | ||
"briefResultsDescription" : "Intensive methotrexate dosing better than conventional", | "briefResultsDescription" : "Intensive methotrexate dosing better than conventional", | ||
"published" : "2007-11-01", | "published" : "2007-11-01", | ||
| Line 1,104: | Line 452: | ||
"title" : "Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)", | "title" : "Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)", | ||
"pmid" : "17519278" | "pmid" : "17519278" | ||
}, | }, | ||
{ | { | ||
| Line 1,134: | Line 463: | ||
"subspecialties" : "Emergency Medicine;Neurology", | "subspecialties" : "Emergency Medicine;Neurology", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "GCS score, skull fracture, emesis, age, amnesia, and mechanism predict risk", | "briefResultsDescription" : "GCS score, skull fracture, emesis, age, amnesia, and mechanism predict risk", | ||
"published" : "2001-05-05", | "published" : "2001-05-05", | ||
| Line 1,153: | Line 481: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)", | "expansion" : "Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)", | ||
"briefResultsDescription" : "Canakinumab reduces cardiovascular events in patients with previous MI", | "briefResultsDescription" : "Canakinumab reduces cardiovascular events in patients with previous MI", | ||
"published" : "2017-08-27", | "published" : "2017-08-27", | ||
| Line 1,161: | Line 488: | ||
"title" : "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease", | "title" : "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease", | ||
"pmid" : "28845751" | "pmid" : "28845751" | ||
}, | }, | ||
{ | { | ||
| Line 1,191: | Line 499: | ||
"subspecialties" : "Infectious Disease", | "subspecialties" : "Infectious Disease", | ||
"expansion" : "Community-Acquired Pneumonia—Study on the Initial Treatment with Antibiotics of Lower Respiratory Tract Infections", | "expansion" : "Community-Acquired Pneumonia—Study on the Initial Treatment with Antibiotics of Lower Respiratory Tract Infections", | ||
"briefResultsDescription" : "Beta-lactam alone is noninferior to quinolone or beta-lactam+macrolide", | "briefResultsDescription" : "Beta-lactam alone is noninferior to quinolone or beta-lactam+macrolide", | ||
"published" : "2015-04-02", | "published" : "2015-04-02", | ||
| Line 1,210: | Line 517: | ||
"subspecialties" : "Neurology;Cardiology", | "subspecialties" : "Neurology;Cardiology", | ||
"expansion" : "Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events", | "expansion" : "Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events", | ||
"briefResultsDescription" : "Clopidogrel reduces risk of cardiovascular events", | "briefResultsDescription" : "Clopidogrel reduces risk of cardiovascular events", | ||
"published" : "1996-11-16", | "published" : "1996-11-16", | ||
| Line 1,220: | Line 526: | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-08-10T15:33:15Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Catheter ablation vs. standard therapy in AF+HF", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1707855", | ||
"pageid" : | "pageid" : 3533, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1707855", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : "Marrouche NF, <i>et al</i>. \"Catheter Ablation for Atrial Fibrillation with Heart Failure\". <i>The New England Journal of Medicine</i>. 2018. 378(5):417-27.", | |||
"subspecialties" : "Cardiology", | |||
"expansion" : "Catheter Ablation versus Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation", | |||
"citation" : "Marrouche NF, <i>et al</i>. \"Catheter Ablation for Atrial Fibrillation with Heart Failure\". <i>The New England Journal of Medicine</i>. 2018. 378(5):417-27.", | |||
"subspecialties" : "Cardiology", | |||
"expansion" : "Catheter Ablation versus Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation | |||
"briefResultsDescription" : "Catheter ablation superior to standard therapy in AF and HF", | "briefResultsDescription" : "Catheter ablation superior to standard therapy in AF and HF", | ||
"published" : "2018-02-01", | "published" : "2018-02-01", | ||
| Line 1,294: | Line 542: | ||
"title" : "Catheter Ablation for Atrial Fibrillation with Heart Failure", | "title" : "Catheter Ablation for Atrial Fibrillation with Heart Failure", | ||
"pmid" : "29385358" | "pmid" : "29385358" | ||
}, | }, | ||
{ | { | ||
| Line 1,381: | Line 553: | ||
"subspecialties" : "Neurology", | "subspecialties" : "Neurology", | ||
"expansion" : "Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events", | "expansion" : "Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events", | ||
"briefResultsDescription" : "ASA/clopidogrel decreases stroke rates compared to ASA alone in TIA and high-risk CVA", | "briefResultsDescription" : "ASA/clopidogrel decreases stroke rates compared to ASA alone in TIA and high-risk CVA", | ||
"published" : "2013-07-04", | "published" : "2013-07-04", | ||
| Line 1,400: | Line 571: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance", | "expansion" : "Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance", | ||
"briefResultsDescription" : "Combination therapy no better than aspirin alone, more bleeding", | "briefResultsDescription" : "Combination therapy no better than aspirin alone, more bleeding", | ||
"published" : "2006-04-20", | "published" : "2006-04-20", | ||
| Line 1,410: | Line 580: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2018-04-14T12:16:19Z", | |||
"timestamp" : "2018-04-14T12:16:19Z", | |||
"briefDesignDescription" : "LMWH vs. warfarin in cancer VTE", | "briefDesignDescription" : "LMWH vs. warfarin in cancer VTE", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa025313", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa025313", | ||
| Line 1,533: | Line 589: | ||
"subspecialties" : "Hematology;Oncology", | "subspecialties" : "Hematology;Oncology", | ||
"expansion" : "Comparison of Low Molecular Weight Heparin Versus Oral Anticoagulant Therapy for Long Term Anticoagulation in Cancer Patients With Venous Thromboembolism", | "expansion" : "Comparison of Low Molecular Weight Heparin Versus Oral Anticoagulant Therapy for Long Term Anticoagulation in Cancer Patients With Venous Thromboembolism", | ||
"briefResultsDescription" : "LMWH reduces VTE recurrence in cancer VTE without increasing bleeding risk", | "briefResultsDescription" : "LMWH reduces VTE recurrence in cancer VTE without increasing bleeding risk", | ||
"published" : "2003-07-10", | "published" : "2003-07-10", | ||
| Line 1,541: | Line 596: | ||
"title" : "Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer", | "title" : "Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer", | ||
"pmid" : "12853587" | "pmid" : "12853587" | ||
}, | }, | ||
{ | { | ||
| Line 1,571: | Line 607: | ||
"subspecialties" : "Preventive Medicine;Gastroenterology;Oncology", | "subspecialties" : "Preventive Medicine;Gastroenterology;Oncology", | ||
"expansion" : null, | "expansion" : null, | ||
"briefResultsDescription" : "FIT is noninferior to colonoscopy for detecting colon cancer", | "briefResultsDescription" : "FIT is noninferior to colonoscopy for detecting colon cancer", | ||
"published" : "2012-02-23", | "published" : "2012-02-23", | ||
| Line 1,590: | Line 625: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Carvedilol Or Metoprolol European Trial", | "expansion" : "Carvedilol Or Metoprolol European Trial", | ||
"briefResultsDescription" : "Carvedilol extends survival in HFrEF", | "briefResultsDescription" : "Carvedilol extends survival in HFrEF", | ||
"published" : "2003-07-05", | "published" : "2003-07-05", | ||
| Line 1,609: | Line 643: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "ClOpidogrel and Metoprolol in Myocardial Infarction Trial / Second Chinese Cardiac Study", | "expansion" : "ClOpidogrel and Metoprolol in Myocardial Infarction Trial / Second Chinese Cardiac Study", | ||
"briefResultsDescription" : "High-dose IV and PO metoprolol increases cardiogenic shock", | "briefResultsDescription" : "High-dose IV and PO metoprolol increases cardiogenic shock", | ||
"published" : "2005-11-05", | "published" : "2005-11-05", | ||
| Line 1,628: | Line 661: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "FFR-guided complete revascularization superior to infarct-related artery only PCI", | "briefResultsDescription" : "FFR-guided complete revascularization superior to infarct-related artery only PCI", | ||
"published" : "2017-03-30", | "published" : "2017-03-30", | ||
| Line 1,647: | Line 679: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Cardiovascular Outcomes for People Using Anticoagulation Stratgies", | "expansion" : "Cardiovascular Outcomes for People Using Anticoagulation Stratgies", | ||
"briefResultsDescription" : "Rivaroxaban + ASA superior to placebo + ASA for secondary prevention of CAD", | "briefResultsDescription" : "Rivaroxaban + ASA superior to placebo + ASA for secondary prevention of CAD", | ||
"published" : "2017-08-27", | "published" : "2017-08-27", | ||
| Line 1,666: | Line 697: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Cooperative North Scandinavian Enalapril Survival Study", | "expansion" : "Cooperative North Scandinavian Enalapril Survival Study", | ||
"briefResultsDescription" : "Enalapril ↓mortality in NYHA class IV HFrEF", | "briefResultsDescription" : "Enalapril ↓mortality in NYHA class IV HFrEF", | ||
"published" : "1987-06-04", | "published" : "1987-06-04", | ||
| Line 1,685: | Line 715: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Carvedilol Prospective Randomized Cumulative Survival", | "expansion" : "Carvedilol Prospective Randomized Cumulative Survival", | ||
"briefResultsDescription" : "Carvedilol reduces mortality and HF hospitalizations in severe NYHA class III-IV HFrEF", | "briefResultsDescription" : "Carvedilol reduces mortality and HF hospitalizations in severe NYHA class III-IV HFrEF", | ||
"published" : "2002-10-22", | "published" : "2002-10-22", | ||
| Line 1,695: | Line 724: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-14T14:38:53Z", | |||
"briefDesignDescription" : "PCI vs. medical therapy in CAD", | |||
"timestamp" : "2017-12-14T14:38:53Z", | |||
"briefDesignDescription" : "PCI vs. medical therapy in CAD", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa070829", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa070829", | ||
"pageid" : 21, | "pageid" : 21, | ||
| Line 1,742: | Line 733: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation", | "expansion" : "Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation", | ||
"briefResultsDescription" : "No difference between PCI and OMT in stable CAD", | "briefResultsDescription" : "No difference between PCI and OMT in stable CAD", | ||
"published" : "2007-04-12", | "published" : "2007-04-12", | ||
| Line 1,750: | Line 740: | ||
"title" : "Optimal medical therapy with or without PCI for stable coronary disease", | "title" : "Optimal medical therapy with or without PCI for stable coronary disease", | ||
"pmid" : "17387127" | "pmid" : "17387127" | ||
}, | }, | ||
{ | { | ||
| Line 1,799: | Line 751: | ||
"subspecialties" : "Surgery;Neurology;Cardiology", | "subspecialties" : "Surgery;Neurology;Cardiology", | ||
"expansion" : "Carotid Revascularization Endarterectomy vs. Stenting Trial", | "expansion" : "Carotid Revascularization Endarterectomy vs. Stenting Trial", | ||
"briefResultsDescription" : "No difference in stroke/MI/death; stenting ↑perioperative stroke but ↓perioperative MI", | "briefResultsDescription" : "No difference in stroke/MI/death; stenting ↑perioperative stroke but ↓perioperative MI", | ||
"published" : "2010-07-01", | "published" : "2010-07-01", | ||
| Line 1,807: | Line 758: | ||
"title" : "Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis", | "title" : "Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis", | ||
"pmid" : "20505173" | "pmid" : "20505173" | ||
}, | }, | ||
{ | { | ||
| Line 1,856: | Line 769: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock", | "expansion" : "Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock", | ||
"briefResultsDescription" : "Culprit-only PCI superior to multivessel PCI in cardiogenic shock", | "briefResultsDescription" : "Culprit-only PCI superior to multivessel PCI in cardiogenic shock", | ||
"published" : "2017-10-30", | "published" : "2017-10-30", | ||
| Line 1,866: | Line 778: | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-05-31T17:39:19Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Culprit lesion PCI vs. FFR in multivessel CAD", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60648-1/fulltext", | ||
"pageid" : | "pageid" : 3634, | ||
"pdfurl" : " | "pdfurl" : "https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)60648-1.pdf", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Engstrom T, <i>et al</i>. \"Complete Revascularization Versus Treatment of the Culprit Lesion Only in Patients with ST-segment Elevation Myocardial Infarction and Multivessel Disease\". <i>The Lancet</i>. 2015. 386:665-71.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Third Danish Study of Optimal Acute Treatment of Patients with STEMI: Primary PCI in Multivessel Disease", | |||
"expansion" : "Third Danish Study of Optimal Acute Treatment of Patients with STEMI: Primary PCI in Multivessel Disease | |||
"briefResultsDescription" : "FFR-guided revascularization was superior to culprit-lesion only in multivessel CAD", | "briefResultsDescription" : "FFR-guided revascularization was superior to culprit-lesion only in multivessel CAD", | ||
"published" : "2015-08-15", | "published" : "2015-08-15", | ||
| Line 1,999: | Line 796: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-14T19:02:26Z", | |||
"briefDesignDescription" : "DASH diet in HTN", | |||
"timestamp" : "2017-12-14T19:02:26Z", | |||
"briefDesignDescription" : "DASH diet in HTN", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199704173361601", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199704173361601", | ||
"pageid" : 90, | "pageid" : 90, | ||
| Line 2,046: | Line 805: | ||
"subspecialties" : "Cardiology;Nephrology", | "subspecialties" : "Cardiology;Nephrology", | ||
"expansion" : "Dietary Approaches to Stop Hypertension", | "expansion" : "Dietary Approaches to Stop Hypertension", | ||
"briefResultsDescription" : "DASH diet reduces SBP and DBP", | "briefResultsDescription" : "DASH diet reduces SBP and DBP", | ||
"published" : "1997-04-17", | "published" : "1997-04-17", | ||
| Line 2,054: | Line 812: | ||
"title" : "A clinical trial of the effects of dietary patterns on blood pressure", | "title" : "A clinical trial of the effects of dietary patterns on blood pressure", | ||
"pmid" : "9099655" | "pmid" : "9099655" | ||
}, | }, | ||
{ | { | ||
| Line 2,084: | Line 823: | ||
"subspecialties" : "Endocrinology", | "subspecialties" : "Endocrinology", | ||
"expansion" : "Diabetes Control and Complications Trial", | "expansion" : "Diabetes Control and Complications Trial", | ||
"briefResultsDescription" : "Intensive therapy delays microvascular but not macrovascular complications in T1DM", | "briefResultsDescription" : "Intensive therapy delays microvascular but not macrovascular complications in T1DM", | ||
"published" : "1993-09-30", | "published" : "1993-09-30", | ||
| Line 2,103: | Line 841: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation", | "expansion" : "Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation", | ||
"briefResultsDescription" : "ICD reduced risk of arrhythmogenic sudden death, but not overall mortality", | "briefResultsDescription" : "ICD reduced risk of arrhythmogenic sudden death, but not overall mortality", | ||
"published" : "2004-05-20", | "published" : "2004-05-20", | ||
| Line 2,122: | Line 859: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction", | "expansion" : "Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction", | ||
"briefResultsDescription" : "Oxygen doesn't improve 1 year survival in MI", | "briefResultsDescription" : "Oxygen doesn't improve 1 year survival in MI", | ||
"published" : "2017-09-28", | "published" : "2017-09-28", | ||
| Line 2,141: | Line 877: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Digitalis Investigation Group", | "expansion" : "Digitalis Investigation Group", | ||
"briefResultsDescription" : "Reduced hospitalizations, no mortality benefit", | "briefResultsDescription" : "Reduced hospitalizations, no mortality benefit", | ||
"published" : "1997-02-20", | "published" : "1997-02-20", | ||
| Line 2,149: | Line 884: | ||
"title" : "The effect of digoxin on mortality and morbidity in patients with heart failure", | "title" : "The effect of digoxin on mortality and morbidity in patients with heart failure", | ||
"pmid" : "9036306" | "pmid" : "9036306" | ||
}, | }, | ||
{ | { | ||
| Line 2,198: | Line 895: | ||
"subspecialties" : "Endocrinology", | "subspecialties" : "Endocrinology", | ||
"expansion" : "Diabetes Prevention Program", | "expansion" : "Diabetes Prevention Program", | ||
"briefResultsDescription" : "Metformin and intensive lifestyle reduce incidence of diabetes", | "briefResultsDescription" : "Metformin and intensive lifestyle reduce incidence of diabetes", | ||
"published" : "2002-02-07", | "published" : "2002-02-07", | ||
| Line 2,206: | Line 902: | ||
"title" : "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin", | "title" : "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin", | ||
"pmid" : "11832527" | "pmid" : "11832527" | ||
}, | }, | ||
{ | { | ||
| Line 2,236: | Line 913: | ||
"subspecialties" : "Gastroenterology;Infectious Disease", | "subspecialties" : "Gastroenterology;Infectious Disease", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "Fecal transplant better than vancomycin in C. difficile", | "briefResultsDescription" : "Fecal transplant better than vancomycin in C. difficile", | ||
"published" : "2013-01-31", | "published" : "2013-01-31", | ||
| Line 2,244: | Line 920: | ||
"title" : "Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile", | "title" : "Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile", | ||
"pmid" : "23323867" | "pmid" : "23323867" | ||
}, | }, | ||
{ | { | ||
| Line 2,274: | Line 931: | ||
"subspecialties" : "Gastroenterology;Interventional Radiology", | "subspecialties" : "Gastroenterology;Interventional Radiology", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "Early TIPS reduces rates of treatment failure and improves 1-year survival", | "briefResultsDescription" : "Early TIPS reduces rates of treatment failure and improves 1-year survival", | ||
"published" : "2010-06-24", | "published" : "2010-06-24", | ||
| Line 2,293: | Line 949: | ||
"subspecialties" : "Neurology", | "subspecialties" : "Neurology", | ||
"expansion" : "European Cooperative Acute Stroke Study III", | "expansion" : "European Cooperative Acute Stroke Study III", | ||
"briefResultsDescription" : "Alteplase improves neurological outcomes at 3 months", | "briefResultsDescription" : "Alteplase improves neurological outcomes at 3 months", | ||
"published" : "2008-09-25", | "published" : "2008-09-25", | ||
| Line 2,303: | Line 958: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2013-03-12T08:18:42Z", | |||
"briefDesignDescription" : "Intensive glycemic therapy in T1DM", | |||
"timestamp" : "2013-03-12T08:18:42Z", | |||
"briefDesignDescription" : "Intensive glycemic therapy in T1DM", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa052187", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa052187", | ||
"pageid" : 136, | "pageid" : 136, | ||
| Line 2,331: | Line 967: | ||
"subspecialties" : "Endocrinology", | "subspecialties" : "Endocrinology", | ||
"expansion" : "Epidemiology of Diabetes Interventions and Complications", | "expansion" : "Epidemiology of Diabetes Interventions and Complications", | ||
"briefResultsDescription" : "Intensive therapy associated with fewer cardiovascular complications", | "briefResultsDescription" : "Intensive therapy associated with fewer cardiovascular complications", | ||
"published" : "2005-12-22", | "published" : "2005-12-22", | ||
| Line 2,339: | Line 974: | ||
"title" : "Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes", | "title" : "Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes", | ||
"pmid" : "16371630" | "pmid" : "16371630" | ||
}, | }, | ||
{ | { | ||
| Line 2,407: | Line 985: | ||
"subspecialties" : "Neurology;Cardiology", | "subspecialties" : "Neurology;Cardiology", | ||
"expansion" : "30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation after a Cerebral Ischemic Event", | "expansion" : "30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation after a Cerebral Ischemic Event", | ||
"briefResultsDescription" : "Extended EKG monitoring detects AF more frequently than 24-hour monitoring", | "briefResultsDescription" : "Extended EKG monitoring detects AF more frequently than 24-hour monitoring", | ||
"published" : "2014-06-26", | "published" : "2014-06-26", | ||
| Line 2,417: | Line 994: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2018-03-29T18:53:41Z", | |||
"briefDesignDescription" : "Edoxaban vs. warfarin in AF", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1310907", | |||
"pageid" : 2471, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1310907", | |||
"trainingLevel" : "resident", | |||
"citation" : "Guigliano RP, <i>et al</i>. \"Edoxaban versus warfarin in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2013. 369(22):2093-2104.", | |||
"timestamp" : "2018-03-29T18:53:41Z", | |||
"briefDesignDescription" : "Edoxaban vs. warfarin in AF", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1310907", | |||
"pageid" : 2471, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1310907", | |||
"trainingLevel" : "resident", | |||
"citation" : "Guigliano RP, <i>et al</i>. \"Edoxaban versus warfarin in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2013. 369(22):2093-2104.", | |||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction 48", | "expansion" : "Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction 48", | ||
"briefResultsDescription" : "Edoxaban is noninferior to warfarin to prevent stroke or thromboembolism", | "briefResultsDescription" : "Edoxaban is noninferior to warfarin to prevent stroke or thromboembolism", | ||
"published" : "2013-11-28", | "published" : "2013-11-28", | ||
| Line 2,502: | Line 1,021: | ||
"subspecialties" : "Orthopedics;Hematology;General Medicine", | "subspecialties" : "Orthopedics;Hematology;General Medicine", | ||
"expansion" : "Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty II", | "expansion" : "Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty II", | ||
"briefResultsDescription" : "Aspirin similar to rivaroxaban for prevention of VTE", | "briefResultsDescription" : "Aspirin similar to rivaroxaban for prevention of VTE", | ||
"published" : "2018-02-22", | "published" : "2018-02-22", | ||
| Line 2,521: | Line 1,039: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study", | "expansion" : "Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study", | ||
"briefResultsDescription" : "Mortality benefit of eplerenone post MI with HFrEF", | "briefResultsDescription" : "Mortality benefit of eplerenone post MI with HFrEF", | ||
"published" : "2003-04-03", | "published" : "2003-04-03", | ||
| Line 2,529: | Line 1,046: | ||
"title" : "Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction", | "title" : "Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction", | ||
"pmid" : "12668699" | "pmid" : "12668699" | ||
}, | }, | ||
{ | { | ||
| Line 2,635: | Line 1,057: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease", | "expansion" : "European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease", | ||
"briefResultsDescription" : "Perindopril reduces composite of CV mortality, MI, or cardiac arrest", | "briefResultsDescription" : "Perindopril reduces composite of CV mortality, MI, or cardiac arrest", | ||
"published" : "2003-09-06", | "published" : "2003-09-06", | ||
| Line 2,643: | Line 1,064: | ||
"title" : "Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease", | "title" : "Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease", | ||
"pmid" : "13678872" | "pmid" : "13678872" | ||
}, | }, | ||
{ | { | ||
| Line 2,749: | Line 1,075: | ||
"subspecialties" : "Critical Care", | "subspecialties" : "Critical Care", | ||
"expansion" : "Fluids and Catheters Treatment Trial", | "expansion" : "Fluids and Catheters Treatment Trial", | ||
"briefResultsDescription" : "Mortality benefit of conservative fluid management in ALI/ARDS", | "briefResultsDescription" : "Mortality benefit of conservative fluid management in ALI/ARDS", | ||
"published" : "2006-06-15", | "published" : "2006-06-15", | ||
| Line 2,768: | Line 1,093: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Fractional Flow Reserve versus Angiography for Multivessel Evaluation", | "expansion" : "Fractional Flow Reserve versus Angiography for Multivessel Evaluation", | ||
"briefResultsDescription" : "FFR reduces composite of death, nonfatal MI, urgent revascularization", | "briefResultsDescription" : "FFR reduces composite of death, nonfatal MI, urgent revascularization", | ||
"published" : "2009-01-15", | "published" : "2009-01-15", | ||
| Line 2,787: | Line 1,111: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "FFR vs. Angiographyfor Multivessel Evaluation 2", | "expansion" : "FFR vs. Angiographyfor Multivessel Evaluation 2", | ||
"briefResultsDescription" : "FFR-guided PCI reduces urgent revascularization", | "briefResultsDescription" : "FFR-guided PCI reduces urgent revascularization", | ||
"published" : "2012-09-13", | "published" : "2012-09-13", | ||
| Line 2,795: | Line 1,118: | ||
"title" : "Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease", | "title" : "Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease", | ||
"pmid" : "22924638" | "pmid" : "22924638" | ||
}, | }, | ||
{ | { | ||
| Line 2,825: | Line 1,129: | ||
"subspecialties" : "Infectious Disease;Gastroenterology", | "subspecialties" : "Infectious Disease;Gastroenterology", | ||
"expansion" : null, | "expansion" : null, | ||
"briefResultsDescription" : "Fidaxomicin noninferior to vancomycin for cure, and resulted in 45% fewer recurrences", | "briefResultsDescription" : "Fidaxomicin noninferior to vancomycin for cure, and resulted in 45% fewer recurrences", | ||
"published" : "2011-02-03", | "published" : "2011-02-03", | ||
| Line 2,833: | Line 1,136: | ||
"title" : "Fidaxomicin versus Vancomycin for Clostridium difficile Infection", | "title" : "Fidaxomicin versus Vancomycin for Clostridium difficile Infection", | ||
"pmid" : "21288078" | "pmid" : "21288078" | ||
}, | }, | ||
{ | { | ||
| Line 2,882: | Line 1,147: | ||
"subspecialties" : "Neurology", | "subspecialties" : "Neurology", | ||
"expansion" : "Fluoxetine for Motor Recovery after Acute Ischaemic Stroke", | "expansion" : "Fluoxetine for Motor Recovery after Acute Ischaemic Stroke", | ||
"briefResultsDescription" : "Early fluoxetine improved motor outcomes post stroke", | "briefResultsDescription" : "Early fluoxetine improved motor outcomes post stroke", | ||
"published" : "2011-02-01", | "published" : "2011-02-01", | ||
| Line 2,901: | Line 1,165: | ||
"subspecialties" : "Hematology;Surgery", | "subspecialties" : "Hematology;Surgery", | ||
"expansion" : "Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair", | "expansion" : "Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair", | ||
"briefResultsDescription" : "Liberal transfusions no better than restrictive", | "briefResultsDescription" : "Liberal transfusions no better than restrictive", | ||
"published" : "2011-12-29", | "published" : "2011-12-29", | ||
| Line 2,911: | Line 1,174: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2014-09-24T22:28:37Z", | |||
"briefDesignDescription" : "Lisinopril in acute MI", | |||
"timestamp" : "2014-09-24T22:28:37Z", | |||
"briefDesignDescription" : "Lisinopril in acute MI", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2894%2990232-1/abstract", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2894%2990232-1/abstract", | ||
"pageid" : 258, | "pageid" : 258, | ||
| Line 2,996: | Line 1,183: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico", | "expansion" : "Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico", | ||
"briefResultsDescription" : "Lisinopril improves 6-week mortality", | "briefResultsDescription" : "Lisinopril improves 6-week mortality", | ||
"published" : "1994-05-07", | "published" : "1994-05-07", | ||
| Line 3,004: | Line 1,190: | ||
"title" : "Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction", | "title" : "Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction", | ||
"pmid" : "7910229" | "pmid" : "7910229" | ||
}, | }, | ||
{ | { | ||
| Line 3,034: | Line 1,201: | ||
"subspecialties" : "Critical Care;Neurology;Cardiology", | "subspecialties" : "Critical Care;Neurology;Cardiology", | ||
"expansion" : "Hypothermia After Cardiac Arrest", | "expansion" : "Hypothermia After Cardiac Arrest", | ||
"briefResultsDescription" : "Hypothermia improves neurologic outcomes and reduces mortality", | "briefResultsDescription" : "Hypothermia improves neurologic outcomes and reduces mortality", | ||
"published" : "2002-02-21", | "published" : "2002-02-21", | ||
| Line 3,042: | Line 1,208: | ||
"title" : "Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest", | "title" : "Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest", | ||
"pmid" : "11856793" | "pmid" : "11856793" | ||
}, | }, | ||
{ | { | ||
| Line 3,072: | Line 1,219: | ||
"subspecialties" : "Critical Care;Infectious Disease", | "subspecialties" : "Critical Care;Infectious Disease", | ||
"expansion" : "Permissive Hyperthermia through Avoidance of Acetaminophen in Known or Suspected Infection in the Intensive Care Unit", | "expansion" : "Permissive Hyperthermia through Avoidance of Acetaminophen in Known or Suspected Infection in the Intensive Care Unit", | ||
"briefResultsDescription" : "Acetaminophen does not improves ICU outcomes", | "briefResultsDescription" : "Acetaminophen does not improves ICU outcomes", | ||
"published" : "2015-12-03", | "published" : "2015-12-03", | ||
| Line 3,082: | Line 1,228: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2018- | "timestamp" : "2018-10-25T17:06:10Z", | ||
"briefDesignDescription" : "High dialysis dose and high-flux membrane in hemodialysis", | "briefDesignDescription" : "High dialysis dose and high-flux membrane in hemodialysis", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa021583", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa021583", | ||
| Line 3,089: | Line 1,235: | ||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
"citation" : "Rose EA, <i>et al</i>. \"Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis\". <i>The New England Journal of Medicine</i>. 2002. 347(25):2020-2019.", | "citation" : "Rose EA, <i>et al</i>. \"Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis\". <i>The New England Journal of Medicine</i>. 2002. 347(25):2020-2019.", | ||
"subspecialties" : " | "subspecialties" : "Nephrology", | ||
"expansion" : "Hemodialysis", | "expansion" : "Hemodialysis", | ||
"briefResultsDescription" : "High dialysis dose and high-flux membrane did not reduce all-cause mortality", | "briefResultsDescription" : "High dialysis dose and high-flux membrane did not reduce all-cause mortality", | ||
"published" : "2002-12-19", | "published" : "2002-12-19", | ||
"pageName" : "HEMO", | "pageName" : "HEMO", | ||
"diseases" : "Chronic | "diseases" : "Chronic Kidney Disease", | ||
"abbreviation" : "HEMO", | "abbreviation" : "HEMO", | ||
"title" : "Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis", | "title" : "Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis", | ||
| Line 3,110: | Line 1,255: | ||
"subspecialties" : "Oncology", | "subspecialties" : "Oncology", | ||
"expansion" : "Herceptin Adjuvant Trial", | "expansion" : "Herceptin Adjuvant Trial", | ||
"briefResultsDescription" : "Trastuzumab improves survival", | "briefResultsDescription" : "Trastuzumab improves survival", | ||
"published" : "2005-10-20", | "published" : "2005-10-20", | ||
| Line 3,129: | Line 1,273: | ||
"subspecialties" : "Hematology;Pulmonology", | "subspecialties" : "Hematology;Pulmonology", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "Edoxaban noninferior to dalteparin in cancer VTE", | "briefResultsDescription" : "Edoxaban noninferior to dalteparin in cancer VTE", | ||
"published" : "2018-02-15", | "published" : "2018-02-15", | ||
| Line 3,148: | Line 1,291: | ||
"subspecialties" : "Cardiology;Neurology", | "subspecialties" : "Cardiology;Neurology", | ||
"expansion" : "Heart Outcomes Prevention Evaluation", | "expansion" : "Heart Outcomes Prevention Evaluation", | ||
"briefResultsDescription" : "Ramipril reduces death, MI, and stroke", | "briefResultsDescription" : "Ramipril reduces death, MI, and stroke", | ||
"published" : "2000-01-20", | "published" : "2000-01-20", | ||
| Line 3,158: | Line 1,300: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2018-08-14T17:41:27Z", | |||
"briefDesignDescription" : "Hydrocortisone, Vit C, and thiamine in sepsis", | |||
"fulltexturl" : "http://journal.chestnet.org/article/S0012-3692(16)62564-3/fulltext", | |||
"timestamp" : "2018-08-14T17:41:27Z", | |||
"briefDesignDescription" : "Hydrocortisone, Vit C, and thiamine in sepsis", | |||
"fulltexturl" : "http://journal.chestnet.org/article/S0012-3692(16)62564-3/fulltext", | |||
"pageid" : 2946, | "pageid" : 2946, | ||
"pdfurl" : "http://journal.chestnet.org/article/S0012-3692(16)62564-3/pdf", | "pdfurl" : "http://journal.chestnet.org/article/S0012-3692(16)62564-3/pdf", | ||
| Line 3,243: | Line 1,309: | ||
"subspecialties" : "Critical Care;Infectious Disease;Pulmonology", | "subspecialties" : "Critical Care;Infectious Disease;Pulmonology", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "Pilot study with impressive findings, low-quality data", | "briefResultsDescription" : "Pilot study with impressive findings, low-quality data", | ||
"published" : "2017-06-01", | "published" : "2017-06-01", | ||
| Line 3,262: | Line 1,327: | ||
"subspecialties" : "Critical Care", | "subspecialties" : "Critical Care", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "Hydrocortisone not superior to placebo in severe sepsis", | "briefResultsDescription" : "Hydrocortisone not superior to placebo in severe sepsis", | ||
"published" : "2016-10-03", | "published" : "2016-10-03", | ||
| Line 3,281: | Line 1,345: | ||
"subspecialties" : "Nephrology;Cardiology;Geriatrics", | "subspecialties" : "Nephrology;Cardiology;Geriatrics", | ||
"expansion" : "Hypertension in the Very Elderly Trial", | "expansion" : "Hypertension in the Very Elderly Trial", | ||
"briefResultsDescription" : "Trend towards reduction in stroke with treatment (P", | "briefResultsDescription" : "Trend towards reduction in stroke with treatment (P", | ||
"published" : "2008-05-01", | "published" : "2008-05-01", | ||
| Line 3,300: | Line 1,363: | ||
"subspecialties" : "Cardiology;Critical Care", | "subspecialties" : "Cardiology;Critical Care", | ||
"expansion" : "Intraaortic Balloon Pump in Cardiogenic Shock II", | "expansion" : "Intraaortic Balloon Pump in Cardiogenic Shock II", | ||
"briefResultsDescription" : "IABP did not reduce mortality at 30 days", | "briefResultsDescription" : "IABP did not reduce mortality at 30 days", | ||
"published" : "2012-10-10", | "published" : "2012-10-10", | ||
| Line 3,319: | Line 1,381: | ||
"subspecialties" : "Hematology", | "subspecialties" : "Hematology", | ||
"expansion" : null, | "expansion" : null, | ||
"briefResultsDescription" : "Ibrutinib is safe and effective in previously treated WM", | "briefResultsDescription" : "Ibrutinib is safe and effective in previously treated WM", | ||
"published" : "2015-04-09", | "published" : "2015-04-09", | ||
| Line 3,329: | Line 1,390: | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-14T19:46:19Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Ezetimibe+simvastatin after ACS", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1410489", | ||
"pageid" : | "pageid" : 2369, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1410489", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Cannon CP, <i>et al</i>. \"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes\". <i>The New England Journal of Medicine</i>. 2015. 375(25):2387-2397.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "IMProved Reduction of Outcomes: Vytorin Efficacy International Trial", | ||
"briefResultsDescription" : "Ezetimibe improves CV outcomes when added to statin", | |||
"briefResultsDescription" : " | "published" : "2015-06-18", | ||
"published" : " | "pageName" : "IMPROVE-IT", | ||
"pageName" : " | "diseases" : "Hyperlipidemia;Acute Coronary Syndrome;Myocardial Infarction", | ||
"diseases" : " | "abbreviation" : "IMPROVE-IT", | ||
"abbreviation" : " | "title" : "Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes", | ||
"title" : " | "pmid" : "26039521" | ||
"pmid" : " | |||
}, | }, | ||
{ | { | ||
"timestamp" : "2018-03-30T14:11:39Z", | |||
"briefDesignDescription" : "Nintedanib in IPF", | |||
"timestamp" : "2018-03-30T14:11:39Z", | |||
"briefDesignDescription" : "Nintedanib in IPF", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1402584", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1402584", | ||
"pageid" : 2934, | "pageid" : 2934, | ||
| Line 3,433: | Line 1,417: | ||
"subspecialties" : "Pulmonology", | "subspecialties" : "Pulmonology", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "Nintedanib slows progression of IPF", | "briefResultsDescription" : "Nintedanib slows progression of IPF", | ||
"published" : "2014-05-29", | "published" : "2014-05-29", | ||
| Line 3,443: | Line 1,426: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-20T19:04:02Z", | |||
"briefDesignDescription" : "Aspirin ± streptokinase in acute MI", | |||
"timestamp" : "2017-12-20T19:04:02Z", | |||
"briefDesignDescription" : "Aspirin ± streptokinase in acute MI", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)92833-4/abstract", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)92833-4/abstract", | ||
"pageid" : 133, | "pageid" : 133, | ||
| Line 3,547: | Line 1,435: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Second International Study of Infarct Survival", | "expansion" : "Second International Study of Infarct Survival", | ||
"briefResultsDescription" : "Mortality benefit of aspirin within 24 hours of acute MI", | "briefResultsDescription" : "Mortality benefit of aspirin within 24 hours of acute MI", | ||
"published" : "1988-08-13", | "published" : "1988-08-13", | ||
| Line 3,566: | Line 1,453: | ||
"subspecialties" : "Neurology", | "subspecialties" : "Neurology", | ||
"expansion" : "International Stroke Trial", | "expansion" : "International Stroke Trial", | ||
"briefResultsDescription" : "Mortality benefit with aspirin", | "briefResultsDescription" : "Mortality benefit with aspirin", | ||
"published" : "1997-05-31", | "published" : "1997-05-31", | ||
| Line 3,574: | Line 1,460: | ||
"title" : "The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke", | "title" : "The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke", | ||
"pmid" : "9174558" | "pmid" : "9174558" | ||
}, | |||
{ | |||
"timestamp" : "2018-02-25T17:56:08Z", | |||
"briefDesignDescription" : "Liraglutide and CVD endpoints in T2DM", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1603827", | |||
"pageid" : 2803, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1603827", | |||
"trainingLevel" : "Resident", | |||
"citation" : "Marso SP, <i>et al</i>. \"Liraglutide and cardiovascular outcomes in type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2016. 375(4):311-322.", | |||
"subspecialties" : "Cardiology;Endocrinology", | |||
"expansion" : "Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results", | |||
"briefResultsDescription" : "Liraglutide reduces CV mortality in T2DM", | |||
"published" : "2016-06-28", | |||
"pageName" : "LEADER", | |||
"diseases" : "Diabetes Mellitus;Cardiovascular Disease", | |||
"abbreviation" : "LEADER", | |||
"title" : "Liraglutide and cardiovascular outcomes in type 2 diabetes", | |||
"pmid" : "27295427" | |||
}, | |||
{ | |||
"timestamp" : "2018-10-25T17:05:24Z", | |||
"briefDesignDescription" : "Lenalidomide/dexamethasone in smoldering MM", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1300439", | |||
"pageid" : 3706, | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1300439", | |||
"trainingLevel" : "Fellow", | |||
"citation" : "Mateos MV, <i>et al</i>. \"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma\". <i>The New England Journal of Medicine</i>. 2013. 369(5):438-47.", | |||
"subspecialties" : "Hematology;Oncology", | |||
"expansion" : "", | |||
"briefResultsDescription" : "In flawed trial, LenDex improved OS compared to observation", | |||
"published" : "2013-08-01", | |||
"pageName" : "LenDex in High-Risk Smoldering Myeloma", | |||
"diseases" : "Multiple Myeloma", | |||
"abbreviation" : "", | |||
"title" : "Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma", | |||
"pmid" : "23902483" | |||
}, | |||
{ | |||
"timestamp" : "2018-02-25T17:56:08Z", | |||
"briefDesignDescription" : "Liraglutide and CVD endpoints in T2DM", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1603827", | |||
"pageid" : 2803, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1603827", | |||
"trainingLevel" : "Resident", | |||
"citation" : "Marso SP, <i>et al</i>. \"Liraglutide and cardiovascular outcomes in type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2016. 375(4):311-322.", | |||
"subspecialties" : "Cardiology;Endocrinology", | |||
"expansion" : "Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results | |||
"briefResultsDescription" : "Liraglutide reduces CV mortality in T2DM", | |||
"published" : "2016-06-28", | |||
"pageName" : "LEADER", | |||
"diseases" : "Diabetes Mellitus;Cardiovascular Disease", | |||
"abbreviation" : "LEADER", | |||
"title" : "Liraglutide and cardiovascular outcomes in type 2 diabetes", | |||
"pmid" : "27295427" | |||
}, | |||
{ | |||
"timestamp" : " | |||
"briefDesignDescription" : " | |||
"fulltexturl" : " | |||
"pageid" : | |||
"pdfurl" : " | |||
"trainingLevel" : " | |||
"citation" : " | |||
"subspecialties" : " | |||
"expansion" : " | |||
" | |||
"published" : " | |||
"pageName" : " | |||
"diseases" : " | |||
"abbreviation" : " | |||
"title" : " | |||
"pmid" : " | |||
}, | }, | ||
{ | { | ||
| Line 3,661: | Line 1,507: | ||
"subspecialties" : "Critical Care;Endocrinology", | "subspecialties" : "Critical Care;Endocrinology", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "Intensive glycemic control reduces mortality", | "briefResultsDescription" : "Intensive glycemic control reduces mortality", | ||
"published" : "2001-11-08", | "published" : "2001-11-08", | ||
| Line 3,669: | Line 1,514: | ||
"title" : "Intensive Insulin Therapy in Critically Ill Patients", | "title" : "Intensive Insulin Therapy in Critically Ill Patients", | ||
"pmid" : "11794168" | "pmid" : "11794168" | ||
}, | }, | ||
{ | { | ||
| Line 3,756: | Line 1,525: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Multicenter Automatic Defibrillator Implantation Trial II", | "expansion" : "Multicenter Automatic Defibrillator Implantation Trial II", | ||
"briefResultsDescription" : "ICD improves survival in post-MI patients with LVEF≤30%", | "briefResultsDescription" : "ICD improves survival in post-MI patients with LVEF≤30%", | ||
"published" : "2002-03-21", | "published" : "2002-03-21", | ||
| Line 3,764: | Line 1,532: | ||
"title" : "Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction", | "title" : "Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction", | ||
"pmid" : "11907286" | "pmid" : "11907286" | ||
}, | }, | ||
{ | { | ||
| Line 3,794: | Line 1,543: | ||
"subspecialties" : "Hematology;Cardiology", | "subspecialties" : "Hematology;Cardiology", | ||
"expansion" : "Medically Ill Patient Assessment of Rivaroxaban versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk", | "expansion" : "Medically Ill Patient Assessment of Rivaroxaban versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk", | ||
"briefResultsDescription" : "Rivaroxaban does not prevent VTE in medically ill patients", | "briefResultsDescription" : "Rivaroxaban does not prevent VTE in medically ill patients", | ||
"published" : "2017-08-27", | "published" : "2017-08-27", | ||
| Line 3,802: | Line 1,550: | ||
"title" : "Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness", | "title" : "Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness", | ||
"pmid" : "30145946" | "pmid" : "30145946" | ||
}, | }, | ||
{ | { | ||
| Line 3,851: | Line 1,561: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure", | "expansion" : "Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure", | ||
"briefResultsDescription" : "Metoprolol improves survival in NYHA II-IV HFrEF", | "briefResultsDescription" : "Metoprolol improves survival in NYHA II-IV HFrEF", | ||
"published" : "1999-06-12", | "published" : "1999-06-12", | ||
| Line 3,859: | Line 1,568: | ||
"title" : "Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure", | "title" : "Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure", | ||
"pmid" : "10376614" | "pmid" : "10376614" | ||
}, | }, | ||
{ | { | ||
| Line 3,908: | Line 1,579: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering", | "expansion" : "Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering", | ||
"briefResultsDescription" : "Atorvastatin reduced rate of CV events after UA/NSTEMI", | "briefResultsDescription" : "Atorvastatin reduced rate of CV events after UA/NSTEMI", | ||
"published" : "2001-04-04", | "published" : "2001-04-04", | ||
| Line 3,927: | Line 1,597: | ||
"subspecialties" : "Gastroenterology;Infectious Disease", | "subspecialties" : "Gastroenterology;Infectious Disease", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "Bezlotoxumab reduces the rate of recurrent Clostridium difficile Infection", | "briefResultsDescription" : "Bezlotoxumab reduces the rate of recurrent Clostridium difficile Infection", | ||
"published" : "2017-01-26", | "published" : "2017-01-26", | ||
| Line 3,946: | Line 1,615: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3", | "expansion" : "Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3", | ||
"briefResultsDescription" : "Centrifugal-flow LVAD superior to axial-flow LVAD in advanced HF", | "briefResultsDescription" : "Centrifugal-flow LVAD superior to axial-flow LVAD in advanced HF", | ||
"published" : "2018-04-12", | "published" : "2018-04-12", | ||
| Line 3,954: | Line 1,622: | ||
"title" : "Two-year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure", | "title" : "Two-year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure", | ||
"pmid" : "29526139" | "pmid" : "29526139" | ||
}, | }, | ||
{ | { | ||
| Line 4,022: | Line 1,633: | ||
"subspecialties" : "Neurology", | "subspecialties" : "Neurology", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "IA therapy improves outcome without increased mortality or ICH", | "briefResultsDescription" : "IA therapy improves outcome without increased mortality or ICH", | ||
"published" : "2015-01-01", | "published" : "2015-01-01", | ||
| Line 4,030: | Line 1,640: | ||
"title" : "A randomized trial of intraarterial treatment for acute ischemic stroke", | "title" : "A randomized trial of intraarterial treatment for acute ischemic stroke", | ||
"pmid" : "25517348" | "pmid" : "25517348" | ||
}, | }, | ||
{ | { | ||
| Line 4,117: | Line 1,651: | ||
"subspecialties" : "Surgery;Neurology", | "subspecialties" : "Surgery;Neurology", | ||
"expansion" : "North American Symptomatic Carotid Endarterectomy Trial", | "expansion" : "North American Symptomatic Carotid Endarterectomy Trial", | ||
"briefResultsDescription" : "CEA reduces the risk of death or stroke in symptomatic 50-69% carotid stenosis", | "briefResultsDescription" : "CEA reduces the risk of death or stroke in symptomatic 50-69% carotid stenosis", | ||
"published" : "1998-11-12", | "published" : "1998-11-12", | ||
| Line 4,125: | Line 1,658: | ||
"title" : "Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis", | "title" : "Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis", | ||
"pmid" : "9811916" | "pmid" : "9811916" | ||
}, | }, | ||
{ | { | ||
| Line 4,193: | Line 1,669: | ||
"subspecialties" : "Critical Care;Endocrinology", | "subspecialties" : "Critical Care;Endocrinology", | ||
"expansion" : "Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation", | "expansion" : "Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation", | ||
"briefResultsDescription" : "Increased mortality targeting euglycemia", | "briefResultsDescription" : "Increased mortality targeting euglycemia", | ||
"published" : "2009-03-26", | "published" : "2009-03-26", | ||
| Line 4,212: | Line 1,687: | ||
"subspecialties" : "Neurology;Critical Care", | "subspecialties" : "Neurology;Critical Care", | ||
"expansion" : "National Institute of Neurological Disorders and Stroke rt-PA Stroke Study", | "expansion" : "National Institute of Neurological Disorders and Stroke rt-PA Stroke Study", | ||
"briefResultsDescription" : "tPA within 3 hours improved outcomes", | "briefResultsDescription" : "tPA within 3 hours improved outcomes", | ||
"published" : "1995-12-14", | "published" : "1995-12-14", | ||
| Line 4,220: | Line 1,694: | ||
"title" : "Tissue Plasminogen Activator for Acute Ischemic Stroke", | "title" : "Tissue Plasminogen Activator for Acute Ischemic Stroke", | ||
"pmid" : "7477192" | "pmid" : "7477192" | ||
}, | }, | ||
{ | { | ||
| Line 4,288: | Line 1,705: | ||
"subspecialties" : "Oncology", | "subspecialties" : "Oncology", | ||
"expansion" : "National Surgical Adjuvant Breast and Bowel Project Trial B-32", | "expansion" : "National Surgical Adjuvant Breast and Bowel Project Trial B-32", | ||
"briefResultsDescription" : "Sentinel lymph node biopsy is equally efficacious but has fewer side effects than ALND", | "briefResultsDescription" : "Sentinel lymph node biopsy is equally efficacious but has fewer side effects than ALND", | ||
"published" : "2010-10-01", | "published" : "2010-10-01", | ||
| Line 4,296: | Line 1,712: | ||
"title" : "Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial", | "title" : "Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial", | ||
"pmid" : "20863759" | "pmid" : "20863759" | ||
}, | }, | ||
{ | { | ||
| Line 4,326: | Line 1,723: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Fifth Organization to Assess Strategies in Acute Ischemic Syndromes", | "expansion" : "Fifth Organization to Assess Strategies in Acute Ischemic Syndromes", | ||
"briefResultsDescription" : "Fondaparinux is non-inferior to enoxaparin in NSTE-ACS", | "briefResultsDescription" : "Fondaparinux is non-inferior to enoxaparin in NSTE-ACS", | ||
"published" : "2006-04-06", | "published" : "2006-04-06", | ||
| Line 4,334: | Line 1,730: | ||
"title" : "Comparison of fondaparinux and enoxaparin in acute coronary syndromes", | "title" : "Comparison of fondaparinux and enoxaparin in acute coronary syndromes", | ||
"pmid" : "16537663" | "pmid" : "16537663" | ||
}, | }, | ||
{ | { | ||
| Line 4,364: | Line 1,741: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not\nAdequately Controlled with Their Lipid Modifying Therapy", | "expansion" : "Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not\nAdequately Controlled with Their Lipid Modifying Therapy", | ||
"briefResultsDescription" : "Alirocumab lowers LDL, reduces non-fatal MI", | "briefResultsDescription" : "Alirocumab lowers LDL, reduces non-fatal MI", | ||
"published" : "2015-04-16", | "published" : "2015-04-16", | ||
| Line 4,383: | Line 1,759: | ||
"subspecialties" : "Gastroenterology", | "subspecialties" : "Gastroenterology", | ||
"expansion" : null, | "expansion" : null, | ||
"briefResultsDescription" : "IV omeprazole reduced 30-day rebleeding", | "briefResultsDescription" : "IV omeprazole reduced 30-day rebleeding", | ||
"published" : "2000-08-03", | "published" : "2000-08-03", | ||
| Line 4,391: | Line 1,766: | ||
"title" : "Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcer", | "title" : "Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcer", | ||
"pmid" : "10922420" | "pmid" : "10922420" | ||
}, | }, | ||
{ | { | ||
| Line 4,440: | Line 1,777: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina", | "expansion" : "Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina", | ||
"briefResultsDescription" : "PCI not superior to medical therapy in stable angina", | "briefResultsDescription" : "PCI not superior to medical therapy in stable angina", | ||
"published" : "2017-11-02", | "published" : "2017-11-02", | ||
| Line 4,448: | Line 1,784: | ||
"title" : "Percutaneous coronary intervention in stable angina", | "title" : "Percutaneous coronary intervention in stable angina", | ||
"pmid" : "29103656" | "pmid" : "29103656" | ||
}, | }, | ||
{ | { | ||
| Line 4,497: | Line 1,795: | ||
"subspecialties" : "Surgery;Gastroenterology", | "subspecialties" : "Surgery;Gastroenterology", | ||
"expansion" : "Minimally Invasive Step Up Approach versus Maximal Necrosectomy in Patients with Acute Necrotising Pancreatitis", | "expansion" : "Minimally Invasive Step Up Approach versus Maximal Necrosectomy in Patients with Acute Necrotising Pancreatitis", | ||
"briefResultsDescription" : "Step-up approach reduces major complications and death", | "briefResultsDescription" : "Step-up approach reduces major complications and death", | ||
"published" : "2010-04-22", | "published" : "2010-04-22", | ||
| Line 4,516: | Line 1,813: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure", | "expansion" : "Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure", | ||
"briefResultsDescription" : "ARNI reduces mortality in HFrEF", | "briefResultsDescription" : "ARNI reduces mortality in HFrEF", | ||
"published" : "2014-08-30", | "published" : "2014-08-30", | ||
| Line 4,524: | Line 1,820: | ||
"title" : "Angiotensin-neprilysin inhibition versus enalapril in heart failure", | "title" : "Angiotensin-neprilysin inhibition versus enalapril in heart failure", | ||
"pmid" : "25176015" | "pmid" : "25176015" | ||
}, | }, | ||
{ | { | ||
| Line 4,668: | Line 1,831: | ||
"subspecialties" : "Gastroenterology", | "subspecialties" : "Gastroenterology", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis", | "briefResultsDescription" : "Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis", | ||
"published" : "2000-12-20", | "published" : "2000-12-20", | ||
| Line 4,676: | Line 1,838: | ||
"title" : "Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial", | "title" : "Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial", | ||
"pmid" : "11113085" | "pmid" : "11113085" | ||
}, | }, | ||
{ | { | ||
| Line 4,725: | Line 1,849: | ||
"subspecialties" : "Pulmonology;Hematology", | "subspecialties" : "Pulmonology;Hematology", | ||
"expansion" : "Prospective Investigation of Pulmonary Embolism Diagnosis II", | "expansion" : "Prospective Investigation of Pulmonary Embolism Diagnosis II", | ||
"briefResultsDescription" : "CT sensitive and specific in detecting acute PE", | "briefResultsDescription" : "CT sensitive and specific in detecting acute PE", | ||
"published" : "2006-06-01", | "published" : "2006-06-01", | ||
| Line 4,733: | Line 1,856: | ||
"title" : "Multidetector Computed Tomography for Acute Pulmonary Embolism", | "title" : "Multidetector Computed Tomography for Acute Pulmonary Embolism", | ||
"pmid" : "16738268" | "pmid" : "16738268" | ||
}, | }, | ||
{ | { | ||
| Line 4,782: | Line 1,867: | ||
"subspecialties" : "Critical Care;Infectious Disease;Pulmonology", | "subspecialties" : "Critical Care;Infectious Disease;Pulmonology", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "8 days of antibiotics are equivalent to 15 days", | "briefResultsDescription" : "8 days of antibiotics are equivalent to 15 days", | ||
"published" : "2003-11-19", | "published" : "2003-11-19", | ||
| Line 4,801: | Line 1,885: | ||
"subspecialties" : "Neurology", | "subspecialties" : "Neurology", | ||
"expansion" : "Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial", | "expansion" : "Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial", | ||
"briefResultsDescription" : "Aspirin/clopidogrel reduces stroke recurrence, increases bleeding compared to aspirin", | "briefResultsDescription" : "Aspirin/clopidogrel reduces stroke recurrence, increases bleeding compared to aspirin", | ||
"published" : "2018-05-16", | "published" : "2018-05-16", | ||
| Line 4,820: | Line 1,903: | ||
"subspecialties" : "Surgery;Cardiology", | "subspecialties" : "Surgery;Cardiology", | ||
"expansion" : "PeriOperative ISchemic Evaluation", | "expansion" : "PeriOperative ISchemic Evaluation", | ||
"briefResultsDescription" : "Perioperative metoprolol reduces MI risk but increases risk of mortality and stroke", | "briefResultsDescription" : "Perioperative metoprolol reduces MI risk but increases risk of mortality and stroke", | ||
"published" : "2008-05-31", | "published" : "2008-05-31", | ||
| Line 4,828: | Line 1,910: | ||
"title" : "Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery: a Randomised Controlled Trial", | "title" : "Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery: a Randomised Controlled Trial", | ||
"pmid" : "18479744" | "pmid" : "18479744" | ||
}, | }, | ||
{ | { | ||
| Line 4,896: | Line 1,921: | ||
"subspecialties" : "Cardiology;Rheumatology;Neurology", | "subspecialties" : "Cardiology;Rheumatology;Neurology", | ||
"expansion" : "Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen", | "expansion" : "Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen", | ||
"briefResultsDescription" : "Celecoxib noninferior to ibuprofen or naproxen with regard to CV safety", | "briefResultsDescription" : "Celecoxib noninferior to ibuprofen or naproxen with regard to CV safety", | ||
"published" : "2016-12-29", | "published" : "2016-12-29", | ||
| Line 4,915: | Line 1,939: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Prevención con Dieta Mediterránea", | "expansion" : "Prevención con Dieta Mediterránea", | ||
"briefResultsDescription" : "Mediterranean diet reduces composite rate of MI/CVA/CV death", | "briefResultsDescription" : "Mediterranean diet reduces composite rate of MI/CVA/CV death", | ||
"published" : "2013-02-25", | "published" : "2013-02-25", | ||
| Line 4,934: | Line 1,957: | ||
"subspecialties" : "Gastroenterology", | "subspecialties" : "Gastroenterology", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "Prednisolone improves short-term survival", | "briefResultsDescription" : "Prednisolone improves short-term survival", | ||
"published" : "1992-02-20", | "published" : "1992-02-20", | ||
| Line 4,942: | Line 1,964: | ||
"title" : "A randomized trial of prednisolone in patients with severe alcoholic hepatitis", | "title" : "A randomized trial of prednisolone in patients with severe alcoholic hepatitis", | ||
"pmid" : "1531090" | "pmid" : "1531090" | ||
}, | }, | ||
{ | { | ||
| Line 5,086: | Line 1,975: | ||
"subspecialties" : "Critical Care;Infectious Disease", | "subspecialties" : "Critical Care;Infectious Disease", | ||
"expansion" : "Procalcitonin to Reduce Antibiotic Treatments in Acutely ill patients", | "expansion" : "Procalcitonin to Reduce Antibiotic Treatments in Acutely ill patients", | ||
"briefResultsDescription" : "Procalcitonin noninferior and led to fewer days on antibiotics", | "briefResultsDescription" : "Procalcitonin noninferior and led to fewer days on antibiotics", | ||
"published" : "2010-02-06", | "published" : "2010-02-06", | ||
| Line 5,094: | Line 1,982: | ||
"title" : "Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units", | "title" : "Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units", | ||
"pmid" : "20097417" | "pmid" : "20097417" | ||
}, | }, | ||
{ | { | ||
| Line 5,124: | Line 1,993: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation", | "expansion" : "WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation", | ||
"briefResultsDescription" : "LAA closure was noninferior to warfarin therapy", | "briefResultsDescription" : "LAA closure was noninferior to warfarin therapy", | ||
"published" : "2009-11-07", | "published" : "2009-11-07", | ||
| Line 5,143: | Line 2,011: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22", | "expansion" : "Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22", | ||
"briefResultsDescription" : "High-dose atorvastatin is superior to moderate-dose pravastatin at reducing CV events after ACS", | "briefResultsDescription" : "High-dose atorvastatin is superior to moderate-dose pravastatin at reducing CV events after ACS", | ||
"published" : "2004-04-08", | "published" : "2004-04-08", | ||
| Line 5,151: | Line 2,018: | ||
"title" : "Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes", | "title" : "Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes", | ||
"pmid" : "15007110" | "pmid" : "15007110" | ||
}, | }, | ||
{ | { | ||
| Line 5,200: | Line 2,029: | ||
"subspecialties" : "Critical care;Endocrinology", | "subspecialties" : "Critical care;Endocrinology", | ||
"expansion" : "Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes", | "expansion" : "Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes", | ||
"briefResultsDescription" : "Basal-bolus more effective for glycemic control compared to sliding-scale insulin", | "briefResultsDescription" : "Basal-bolus more effective for glycemic control compared to sliding-scale insulin", | ||
"published" : "2007-09-30", | "published" : "2007-09-30", | ||
| Line 5,219: | Line 2,047: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II", | "expansion" : "Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II", | ||
"briefResultsDescription" : "Lenient rate control is as effective as strict rate control", | "briefResultsDescription" : "Lenient rate control is as effective as strict rate control", | ||
"published" : "2010-04-15", | "published" : "2010-04-15", | ||
| Line 5,227: | Line 2,054: | ||
"title" : "Lenient versus Strict Rate Control in Patients with Atrial Fibrillation", | "title" : "Lenient versus Strict Rate Control in Patients with Atrial Fibrillation", | ||
"pmid" : "20231232" | "pmid" : "20231232" | ||
}, | }, | ||
{ | { | ||
| Line 5,257: | Line 2,065: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Randomized Aldactone Evaluation Study", | "expansion" : "Randomized Aldactone Evaluation Study", | ||
"briefResultsDescription" : "Spironolactone reduces all-cause mortality by 30% in severe HFrEF", | "briefResultsDescription" : "Spironolactone reduces all-cause mortality by 30% in severe HFrEF", | ||
"published" : "1999-09-02", | "published" : "1999-09-02", | ||
| Line 5,265: | Line 2,072: | ||
"title" : "The effect of spironolactone on morbidity and mortality in patients with severe heart failure", | "title" : "The effect of spironolactone on morbidity and mortality in patients with severe heart failure", | ||
"pmid" : "10471456" | "pmid" : "10471456" | ||
}, | }, | ||
{ | { | ||
| Line 5,333: | Line 2,083: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Randomized evaluation of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin in patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention", | "expansion" : "Randomized evaluation of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin in patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention", | ||
"briefResultsDescription" : "Aspirin and dabigatran nonferior to triple therapy in patients with AF undergoing PCI", | "briefResultsDescription" : "Aspirin and dabigatran nonferior to triple therapy in patients with AF undergoing PCI", | ||
"published" : "2017-10-19", | "published" : "2017-10-19", | ||
| Line 5,352: | Line 2,101: | ||
"subspecialties" : "Cardiology;Neurology", | "subspecialties" : "Cardiology;Neurology", | ||
"expansion" : "Randomized Evaluation of Long-Term Anticoagulation Therapy", | "expansion" : "Randomized Evaluation of Long-Term Anticoagulation Therapy", | ||
"briefResultsDescription" : "High-dose dabigatran reduces stroke risk without increasing major bleeding in atrial fibrillation", | "briefResultsDescription" : "High-dose dabigatran reduces stroke risk without increasing major bleeding in atrial fibrillation", | ||
"published" : "2009-09-17", | "published" : "2009-09-17", | ||
| Line 5,360: | Line 2,108: | ||
"title" : "Dabigatran versus warfarin in patients with atrial fibrillation", | "title" : "Dabigatran versus warfarin in patients with atrial fibrillation", | ||
"pmid" : "19717844" | "pmid" : "19717844" | ||
}, | }, | ||
{ | { | ||
| Line 5,466: | Line 2,119: | ||
"subspecialties" : "Surgery;Neurology", | "subspecialties" : "Surgery;Neurology", | ||
"expansion" : "Randomised Evaluation of Surgery with Craniectomy for Uncontrollable Elevation of Intracranial Pressure", | "expansion" : "Randomised Evaluation of Surgery with Craniectomy for Uncontrollable Elevation of Intracranial Pressure", | ||
"briefResultsDescription" : "Craniectomy reduced mortality by 22% compared to usual care", | "briefResultsDescription" : "Craniectomy reduced mortality by 22% compared to usual care", | ||
"published" : "2016-09-22", | "published" : "2016-09-22", | ||
| Line 5,474: | Line 2,126: | ||
"title" : "Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension", | "title" : "Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension", | ||
"pmid" : "27602507" | "pmid" : "27602507" | ||
}, | }, | ||
{ | { | ||
| Line 5,523: | Line 2,137: | ||
"subspecialties" : "Critical Care;Emergency Medicine", | "subspecialties" : "Critical Care;Emergency Medicine", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "Early goal-directed therapy decreased mortality and morbiditiy in sepsis", | "briefResultsDescription" : "Early goal-directed therapy decreased mortality and morbiditiy in sepsis", | ||
"published" : "2001-11-08", | "published" : "2001-11-08", | ||
| Line 5,531: | Line 2,144: | ||
"title" : "Early Goal Directed Therapy in the Treatment of Severe Sepsis and Septic Shock", | "title" : "Early Goal Directed Therapy in the Treatment of Severe Sepsis and Septic Shock", | ||
"pmid" : "11794169" | "pmid" : "11794169" | ||
}, | }, | ||
{ | { | ||
| Line 5,561: | Line 2,155: | ||
"subspecialties" : "Psychiatry;Cardiology", | "subspecialties" : "Psychiatry;Cardiology", | ||
"expansion" : "Sertraline Antidepressant Heart Attack Randomized Trial", | "expansion" : "Sertraline Antidepressant Heart Attack Randomized Trial", | ||
"briefResultsDescription" : "Sertraline improves symptoms without adverse CV effects", | "briefResultsDescription" : "Sertraline improves symptoms without adverse CV effects", | ||
"published" : "2002-08-14", | "published" : "2002-08-14", | ||
| Line 5,580: | Line 2,173: | ||
"subspecialties" : "Critical Care", | "subspecialties" : "Critical Care", | ||
"expansion" : "Saline versus Albumin Fluid Evaluation", | "expansion" : "Saline versus Albumin Fluid Evaluation", | ||
"briefResultsDescription" : "No mortality difference (except worse mortality with albumin for TBI)", | "briefResultsDescription" : "No mortality difference (except worse mortality with albumin for TBI)", | ||
"published" : "2004-05-27", | "published" : "2004-05-27", | ||
| Line 5,599: | Line 2,191: | ||
"subspecialties" : "Critical Care;Nephrology", | "subspecialties" : "Critical Care;Nephrology", | ||
"expansion" : "Saline Against Lactated Ringer's or Plasma-Lyte in the Emergency Department", | "expansion" : "Saline Against Lactated Ringer's or Plasma-Lyte in the Emergency Department", | ||
"briefResultsDescription" : "Balanced crystalloids result in fewer renal abnormalities", | "briefResultsDescription" : "Balanced crystalloids result in fewer renal abnormalities", | ||
"published" : "2018-03-01", | "published" : "2018-03-01", | ||
| Line 5,607: | Line 2,198: | ||
"title" : "Balanced crystalloids versus saline in noncritically ill adults", | "title" : "Balanced crystalloids versus saline in noncritically ill adults", | ||
"pmid" : "29485926" | "pmid" : "29485926" | ||
}, | }, | ||
{ | { | ||
| Line 5,637: | Line 2,209: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Survival and Ventricular Enlargement Trial", | "expansion" : "Survival and Ventricular Enlargement Trial", | ||
"briefResultsDescription" : "Captopril improves survival", | "briefResultsDescription" : "Captopril improves survival", | ||
"published" : "1992-09-03", | "published" : "1992-09-03", | ||
| Line 5,656: | Line 2,227: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Sudden Cardiac Death in Heart Failure Trial", | "expansion" : "Sudden Cardiac Death in Heart Failure Trial", | ||
"briefResultsDescription" : "ICD reduces mortality by 23% in class II-III HFrEF", | "briefResultsDescription" : "ICD reduces mortality by 23% in class II-III HFrEF", | ||
"published" : "2005-01-20", | "published" : "2005-01-20", | ||
| Line 5,664: | Line 2,234: | ||
"title" : "Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure", | "title" : "Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure", | ||
"pmid" : "15659722" | "pmid" : "15659722" | ||
}, | }, | ||
{ | { | ||
| Line 5,770: | Line 2,245: | ||
"subspecialties" : "Critical Care;Nephrology", | "subspecialties" : "Critical Care;Nephrology", | ||
"expansion" : "Isotonic Solutions and Major Adverse Renal Events Trial", | "expansion" : "Isotonic Solutions and Major Adverse Renal Events Trial", | ||
"briefResultsDescription" : "Balanced crystalloids slightly reduced composite rate of death, RRT, or CKD", | "briefResultsDescription" : "Balanced crystalloids slightly reduced composite rate of death, RRT, or CKD", | ||
"published" : "2018-03-01", | "published" : "2018-03-01", | ||
| Line 5,789: | Line 2,263: | ||
"subspecialties" : "Critical Care;Emergency Medicine", | "subspecialties" : "Critical Care;Emergency Medicine", | ||
"expansion" : "Sepsis Occurrence in Acutely Ill Patients II", | "expansion" : "Sepsis Occurrence in Acutely Ill Patients II", | ||
"briefResultsDescription" : "Norepinephrine reduces mortality", | "briefResultsDescription" : "Norepinephrine reduces mortality", | ||
"published" : "2010-03-04", | "published" : "2010-03-04", | ||
| Line 5,797: | Line 2,270: | ||
"title" : "Comparison of dopamine and norepinephrine in the treatment of shock", | "title" : "Comparison of dopamine and norepinephrine in the treatment of shock", | ||
"pmid" : "20200382" | "pmid" : "20200382" | ||
}, | }, | ||
{ | { | ||
| Line 5,846: | Line 2,281: | ||
"subspecialties" : "Oncology;Hematology", | "subspecialties" : "Oncology;Hematology", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "No benefit over age-appropriate screening", | "briefResultsDescription" : "No benefit over age-appropriate screening", | ||
"published" : "2015-08-20", | "published" : "2015-08-20", | ||
| Line 5,854: | Line 2,288: | ||
"title" : "Screening for Occult Cancer in Unprovoked Venous Thromboembolism", | "title" : "Screening for Occult Cancer in Unprovoked Venous Thromboembolism", | ||
"pmid" : "26095467" | "pmid" : "26095467" | ||
}, | }, | ||
{ | { | ||
| Line 5,922: | Line 2,299: | ||
"subspecialties" : "Cardiology;Preventive Medicine", | "subspecialties" : "Cardiology;Preventive Medicine", | ||
"expansion" : "Systolic Blood Pressure Intervention Trial", | "expansion" : "Systolic Blood Pressure Intervention Trial", | ||
"briefResultsDescription" : "SBP <120 improves CV outcomes with increased risks", | "briefResultsDescription" : "SBP <120 improves CV outcomes with increased risks", | ||
"published" : "2015-11-09", | "published" : "2015-11-09", | ||
| Line 5,930: | Line 2,306: | ||
"title" : "A randomized trial of intensive versus standard blood-pressure control", | "title" : "A randomized trial of intensive versus standard blood-pressure control", | ||
"pmid" : "26551272" | "pmid" : "26551272" | ||
}, | }, | ||
{ | { | ||
| Line 5,979: | Line 2,317: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Global Clinical Study of Renal Denervation With the Symplicity Spyral Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension on Standard Medical Therapy", | "expansion" : "Global Clinical Study of Renal Denervation With the Symplicity Spyral Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension on Standard Medical Therapy", | ||
"briefResultsDescription" : "Renal denervation+meds is superior to medical therapy alone in resistant hypertension", | "briefResultsDescription" : "Renal denervation+meds is superior to medical therapy alone in resistant hypertension", | ||
"published" : "2018-06-09", | "published" : "2018-06-09", | ||
| Line 5,987: | Line 2,324: | ||
"title" : "Effect of renal denervation on blood pressure in the presence of antihypertensive drugs", | "title" : "Effect of renal denervation on blood pressure in the presence of antihypertensive drugs", | ||
"pmid" : "29803589" | "pmid" : "29803589" | ||
}, | }, | ||
{ | { | ||
| Line 6,169: | Line 2,335: | ||
"subspecialties" : "Psychiatry", | "subspecialties" : "Psychiatry", | ||
"expansion" : "", | "expansion" : "", | ||
"briefResultsDescription" : "Symptom-triggered therapy reduces length of hospitalization without increasing adverse event risk", | "briefResultsDescription" : "Symptom-triggered therapy reduces length of hospitalization without increasing adverse event risk", | ||
"published" : "2002-05-27", | "published" : "2002-05-27", | ||
| Line 6,177: | Line 2,342: | ||
"title" : "Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial", | "title" : "Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial", | ||
"pmid" : "12020181" | "pmid" : "12020181" | ||
}, | }, | ||
{ | { | ||
| Line 6,245: | Line 2,353: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "The Timing of Intervention in Acute Coronary Syndromes", | "expansion" : "The Timing of Intervention in Acute Coronary Syndromes", | ||
"briefResultsDescription" : "Early intervention does not differ greatly from delayed intervention in low- to moderate-risk patients", | "briefResultsDescription" : "Early intervention does not differ greatly from delayed intervention in low- to moderate-risk patients", | ||
"published" : "2009-05-21", | "published" : "2009-05-21", | ||
| Line 6,264: | Line 2,371: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Treating to New Targets", | "expansion" : "Treating to New Targets", | ||
"briefResultsDescription" : "Atorvastatin 80 mg better than 10 mg for major CV events in stable CAD", | "briefResultsDescription" : "Atorvastatin 80 mg better than 10 mg for major CV events in stable CAD", | ||
"published" : "2005-04-07", | "published" : "2005-04-07", | ||
| Line 6,283: | Line 2,389: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Trial of Nonpharmacologic Interventions in the Elderly", | "expansion" : "Trial of Nonpharmacologic Interventions in the Elderly", | ||
"briefResultsDescription" : "Na reduction and weight loss are effective means for hypertension control in the elderly", | "briefResultsDescription" : "Na reduction and weight loss are effective means for hypertension control in the elderly", | ||
"published" : "1998-03-18", | "published" : "1998-03-18", | ||
| Line 6,291: | Line 2,396: | ||
"title" : "Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group", | "title" : "Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group", | ||
"pmid" : "9515998" | "pmid" : "9515998" | ||
}, | }, | ||
{ | { | ||
| Line 6,321: | Line 2,407: | ||
"subspecialties" : "Pulmonology", | "subspecialties" : "Pulmonology", | ||
"expansion" : "Towards a Revolution in COPD Health", | "expansion" : "Towards a Revolution in COPD Health", | ||
"briefResultsDescription" : "Trend towards mortality benefit", | "briefResultsDescription" : "Trend towards mortality benefit", | ||
"published" : "2007-02-22", | "published" : "2007-02-22", | ||
| Line 6,329: | Line 2,414: | ||
"title" : "Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease", | "title" : "Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease", | ||
"pmid" : "17314337" | "pmid" : "17314337" | ||
}, | }, | ||
{ | { | ||
| Line 6,359: | Line 2,425: | ||
"subspecialties" : "Hematology;Rheumatology", | "subspecialties" : "Hematology;Rheumatology", | ||
"expansion" : "Trial on Rivaroxaban in AntiPhospholipid Syndrome", | "expansion" : "Trial on Rivaroxaban in AntiPhospholipid Syndrome", | ||
"briefResultsDescription" : "Rivaroxaban inferior to warfarin in high-risk APLS", | "briefResultsDescription" : "Rivaroxaban inferior to warfarin in high-risk APLS", | ||
"published" : "2018-09-27", | "published" : "2018-09-27", | ||
| Line 6,378: | Line 2,443: | ||
"subspecialties" : "Nephrology;Hematology;Endocrinology", | "subspecialties" : "Nephrology;Hematology;Endocrinology", | ||
"expansion" : "Trial to Reduce Cardiovascular Events With Aranesp Therapy", | "expansion" : "Trial to Reduce Cardiovascular Events With Aranesp Therapy", | ||
"briefResultsDescription" : "No mortality benefit when targeting higher hemoglobin with ESAs in patients with CKD and T2DM", | "briefResultsDescription" : "No mortality benefit when targeting higher hemoglobin with ESAs in patients with CKD and T2DM", | ||
"published" : "2009-11-19", | "published" : "2009-11-19", | ||
| Line 6,397: | Line 2,461: | ||
"subspecialties" : "Critical Care;Hematology", | "subspecialties" : "Critical Care;Hematology", | ||
"expansion" : "Transfusion Requirements in Critical Care", | "expansion" : "Transfusion Requirements in Critical Care", | ||
"briefResultsDescription" : "Restrictive hemoglobin goals improved mortality", | "briefResultsDescription" : "Restrictive hemoglobin goals improved mortality", | ||
"published" : "1999-02-11", | "published" : "1999-02-11", | ||
| Line 6,416: | Line 2,479: | ||
"subspecialties" : "Surgery;Hematology", | "subspecialties" : "Surgery;Hematology", | ||
"expansion" : "Transfusion Requirements in Cardiac Surgery", | "expansion" : "Transfusion Requirements in Cardiac Surgery", | ||
"briefResultsDescription" : "Restrictive noninferior to liberal RBC transfusions", | "briefResultsDescription" : "Restrictive noninferior to liberal RBC transfusions", | ||
"published" : "2017-11-30", | "published" : "2017-11-30", | ||
| Line 6,424: | Line 2,486: | ||
"title" : "Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery", | "title" : "Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery", | ||
"pmid" : "29130845" | "pmid" : "29130845" | ||
}, | }, | ||
{ | { | ||
| Line 6,530: | Line 2,497: | ||
"subspecialties" : "Endocrinology", | "subspecialties" : "Endocrinology", | ||
"expansion" : "United Kingdom Prospective Diabetes Study", | "expansion" : "United Kingdom Prospective Diabetes Study", | ||
"briefResultsDescription" : "Reduction in microvascular complications", | "briefResultsDescription" : "Reduction in microvascular complications", | ||
"published" : "1998-09-12", | "published" : "1998-09-12", | ||
| Line 6,538: | Line 2,504: | ||
"title" : "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes", | "title" : "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes", | ||
"pmid" : "9742976" | "pmid" : "9742976" | ||
}, | }, | ||
{ | { | ||
| Line 6,568: | Line 2,515: | ||
"subspecialties" : "Pulmonology", | "subspecialties" : "Pulmonology", | ||
"expansion" : "Understanding Potential Long-Term Impacts on Function with Tiotropium", | "expansion" : "Understanding Potential Long-Term Impacts on Function with Tiotropium", | ||
"briefResultsDescription" : "Decreased exacerbations and mortality", | "briefResultsDescription" : "Decreased exacerbations and mortality", | ||
"published" : "2008-10-09", | "published" : "2008-10-09", | ||
| Line 6,576: | Line 2,522: | ||
"title" : "A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease", | "title" : "A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease", | ||
"pmid" : "18836213" | "pmid" : "18836213" | ||
}, | }, | ||
{ | { | ||
| Line 6,625: | Line 2,533: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : null, | "expansion" : null, | ||
"briefResultsDescription" : "Aspirin decreases mortality", | "briefResultsDescription" : "Aspirin decreases mortality", | ||
"published" : "1983-08-18", | "published" : "1983-08-18", | ||
| Line 6,644: | Line 2,551: | ||
"subspecialties" : "Nephrology;Endocrinology", | "subspecialties" : "Nephrology;Endocrinology", | ||
"expansion" : "Veterans Affairs Nephropathy in Diabetes", | "expansion" : "Veterans Affairs Nephropathy in Diabetes", | ||
"briefResultsDescription" : "ACE+ARB no more effective than monotherapy, increases complications", | "briefResultsDescription" : "ACE+ARB no more effective than monotherapy, increases complications", | ||
"published" : "2013-11-14", | "published" : "2013-11-14", | ||
| Line 6,663: | Line 2,569: | ||
"subspecialties" : "Endocrinology", | "subspecialties" : "Endocrinology", | ||
"expansion" : "Veterans Affairs Diabetes Trial", | "expansion" : "Veterans Affairs Diabetes Trial", | ||
"briefResultsDescription" : "No effect on macrovascular or severe microvascular outcomes", | "briefResultsDescription" : "No effect on macrovascular or severe microvascular outcomes", | ||
"published" : "2009-01-08", | "published" : "2009-01-08", | ||
| Line 6,682: | Line 2,587: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Valsartan Heart Failure Trial", | "expansion" : "Valsartan Heart Failure Trial", | ||
"briefResultsDescription" : "No mortality benefit of valsartan in NYHA II-IV HF", | "briefResultsDescription" : "No mortality benefit of valsartan in NYHA II-IV HF", | ||
"published" : "2001-12-06", | "published" : "2001-12-06", | ||
| Line 6,690: | Line 2,594: | ||
"title" : "A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure", | "title" : "A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure", | ||
"pmid" : "11759645" | "pmid" : "11759645" | ||
}, | }, | ||
{ | { | ||
| Line 6,720: | Line 2,605: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Valsartan in Acute Myocardial Infarction Trial", | "expansion" : "Valsartan in Acute Myocardial Infarction Trial", | ||
"briefResultsDescription" : "Valsartan as effective as captopril", | "briefResultsDescription" : "Valsartan as effective as captopril", | ||
"published" : "2003-11-13", | "published" : "2003-11-13", | ||
| Line 6,739: | Line 2,623: | ||
"subspecialties" : "Infectious Disease;Gastroenterology", | "subspecialties" : "Infectious Disease;Gastroenterology", | ||
"expansion" : null, | "expansion" : null, | ||
"briefResultsDescription" : "Vancomycin is superior to metronidazole in severe C. difficile-associated diarrhea", | "briefResultsDescription" : "Vancomycin is superior to metronidazole in severe C. difficile-associated diarrhea", | ||
"published" : "2007-08-01", | "published" : "2007-08-01", | ||
| Line 6,747: | Line 2,630: | ||
"title" : "A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity", | "title" : "A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity", | ||
"pmid" : "17599306" | "pmid" : "17599306" | ||
}, | }, | ||
{ | { | ||
| Line 6,872: | Line 2,641: | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "West of Scotland Coronary Prevention Study", | "expansion" : "West of Scotland Coronary Prevention Study", | ||
"briefResultsDescription" : "Pravastatin reduces MIs and CV mortality", | "briefResultsDescription" : "Pravastatin reduces MIs and CV mortality", | ||
"published" : "1995-11-16", | "published" : "1995-11-16", | ||
| Line 6,880: | Line 2,648: | ||
"title" : "Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia", | "title" : "Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia", | ||
"pmid" : "7566020" | "pmid" : "7566020" | ||
} | } | ||
] | ] | ||
} | } | ||
} | } | ||